SYBX - マイア―ルエヌエイ・セラピュ―ティクス (Synlogic Inc.)

SYBXのニュース

   Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast  2020/03/05 21:02:00 PR Newswire
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines,…
   Synlogic Announces Participation in Upcoming Investor Conferences  2020/02/18 21:02:00 PR Newswire
/PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in…
   Synlogic Appoints Dr. Michael Burgess to its Board of Directors  2020/01/30 11:00:00 PR Newswire
CAMBRIDGE, Mass., Jan. 30, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess, M.B., Ch.B., Ph.D., president of research and…
   Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development  2019/12/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX #PKU--Bridging Study Data from Synlogic's SYNB1618 PKU Candidate Demonstrate Improved Tolerability of New Solid Oral Formulation over Early Liquid
   Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference  2019/11/25 21:02:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX--Synlogic to participate in the Piper Jaffray 31st Annual Healthcare Conference.
   Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast  2020/03/05 21:02:00 PR Newswire
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines,…
   Synlogic Announces Participation in Upcoming Investor Conferences  2020/02/18 21:02:00 PR Newswire
/PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in…
   Synlogic Appoints Dr. Michael Burgess to its Board of Directors  2020/01/30 11:00:00 PR Newswire
CAMBRIDGE, Mass., Jan. 30, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess, M.B., Ch.B., Ph.D., president of research and…
   Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development  2019/12/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX #PKU--Bridging Study Data from Synlogic's SYNB1618 PKU Candidate Demonstrate Improved Tolerability of New Solid Oral Formulation over Early Liquid
   Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference  2019/11/25 21:02:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX--Synlogic to participate in the Piper Jaffray 31st Annual Healthcare Conference.
   Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast  2020/03/05 21:02:00 PR Newswire
/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines,…
   Synlogic Announces Participation in Upcoming Investor Conferences  2020/02/18 21:02:00 PR Newswire
/PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in…
   Synlogic Appoints Dr. Michael Burgess to its Board of Directors  2020/01/30 11:00:00 PR Newswire
CAMBRIDGE, Mass., Jan. 30, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess, M.B., Ch.B., Ph.D., president of research and…
   Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development  2019/12/11 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX #PKU--Bridging Study Data from Synlogic's SYNB1618 PKU Candidate Demonstrate Improved Tolerability of New Solid Oral Formulation over Early Liquid
   Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference  2019/11/25 21:02:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SYBX--Synlogic to participate in the Piper Jaffray 31st Annual Healthcare Conference.

calendar